CellMax is fundamentally and dramatically transforming early cancer detection and prevention. With its patent-pending, simple and accurate blood test, CellMax’s goal is to eventually screen every person in the world. CellMax Life is a global company, currently with offices in U.S. and Taiwan and is funded and backed by leading venture capital firms in Silicon Valley, U.S. and Taiwan.
CellMax Life offers several cell-based and DNA-based cancer screening and surveillance products. The first of its kind, the proprietary Colorectal Cancer (CRC) Tests, if offered directly through its world-class accredited Lab in Taiwan. The immediate goal is to establish the CRC test as the standard for cancer detection and prevention with a longer term goal of eradicating CRC in Taiwan. The technology has successfully been tested on patients, and the success in Taiwan will be the springboard for market entry into China, India and the US.
Cancer is a growing worldwide disease where the outcomes, for the most part, have not changed. The key to increasing overall survival is EARLY DETECTION. However most cancer diagnosis is late stage where the survival rate is very low and the treatment cost is very high. Moreover there is no simple test to monitor for recurrence even after tumor have been removed by surgery and/or chemotherapy treatment has been administered.
The company offers simple blood test that will detect cancer early and also monitor for recurrence.